From AI-driven cancer breakthroughs and non-opioid pain innovation to 5G mmWave expansion, mining advancements, and AI-powered mobility, emerging growth stocks are igniting fresh investor momentum this week. Making headlines with major catalysts and clinical or commercial milestones that align with today’s biggest market trends in AI, biotech, clean tech, and digital transformation.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that its oral drug candidate Mira-55 surpassed injected morphine in normalizing pain and reducing inflammation. These findings, supporting an upcoming IND filing for chronic inflammatory pain, reinforce MIRA’s leadership in the $70 billion non-opioid pain treatment market as the company advances safer, more effective alternatives to opioids. Therefore Oral Mira-55 Outperforms Morphine in Preclinical Study.

Peraso Inc. (NASDAQ: PRSO) reached a new 52-week high of $2.34, climbing over 350% year-to-date, as investors recognize its leadership in 5G mmWave semiconductor technology. The company’s high-performance wireless chipsets, modules, and IP enable fixed wireless access, immersive video, and edge computing—key components of the next-generation connectivity ecosystem driving the AI and IoT markets. Peraso (NAS: PRSO) Issued $2.74 Price Target See Complete Report

Myseum, Inc. (NASDAQ: MYSE) Expands IP Portfolio with New U.S. Patent on Nex-Gen Technology Secure Streaming. Myseum received a U.S. Patent Office Notice of Allowance for its privacy-first streaming technology covering secure real-time video and audio communication. The patent strengthens Myseum’s growing IP base ahead of its upcoming “Picture Party by Myseum” launch—an innovative social platform merging creativity, community, and data privacy. Myseum now holds 18 issued patents, positioning it as a leader in digital privacy and social media innovation.

Aprea Therapeutics, Inc. (NASDAQ: APRE) Establishes Phase 2 Dose for ATRN-119; Targets Combination Therapies. Aprea Therapeutics identified a recommended Phase 2 dose (RP2D) of 1,100 mg once daily for its ATR inhibitor ATRN-119 in the ongoing ABOYA-119 Phase 1/2a trial for solid tumors. The company will now prioritize combination therapy development, exploring synergy with radiation, immunotherapy, and antibody-drug conjugates. Aprea’s lead program, WEE1 kinase inhibitor APR-1051, also continues to show early signs of clinical benefit in advanced solid tumors. Upcoming data will be presented at the AACR-NCI-EORTC Molecular Targets Conference, highlighting Aprea’s expanding footprint in precision oncology and DNA damage repair therapeutics.

Whitehawk Therapeutics Inc. (NASDAQ: WHWK) Leads AI-Powered Oncology Collaboration to Advance Precision Cancer Therapeutics. In a long-term collaboration with Tempus AI (NASDAQ: TEM) to accelerate development of its antibody-drug conjugate (ADC) portfolio using advanced artificial intelligence and real-world clinical data. The partnership will harness Tempus’s AI-driven analytics to enhance trial design and expand the therapeutic potential of Whitehawk’s next-generation oncology assets. This alliance positions Whitehawk at the forefront of AI-enabled precision oncology, targeting faster discovery and improved treatment outcomes for difficult-to-treat cancers.

Roadzen Inc. (NASDAQ: RDZN) Expands Nationwide Across India’s Trucking FleetsRoadzen Inc. announced that its DrivebuddyAI platform has secured contracts with six leading e-commerce trucking fleets in India, deploying its driver-monitoring and collision-warning systems across 1,500 Volvo and BharatBenz trucks. The five-year rollout integrates AI-based safety alerts, fatigue detection, and insurance-linked rewards, strengthening Roadzen’s leadership in AI mobility, telematics, and insurance technology for the fast-scaling logistics sector.

Power Metallic Mines Inc. (TSXV: PNPN | OTCQB: PNPNF) reported progress on metallurgical testing at its Lion polymetallic deposit in Quebec, led by SGS Canada Ltd. The study aims to evaluate recoveries of copper, nickel, gold, and PGEs from high-grade sulphide zones. CEO Terry Lynch noted the approach mirrors the early-stage methodology of projects like Filo Mining and Great Bear, potentially unlocking strong valuation multiples in the critical minerals and gold exploration markets.

From AI-driven cancer analytics to breakthrough pain relief, privacy innovation, and clean resource development, this diverse group of emerging companies exemplifies the convergence of technology and biotechnology fueling today’s markets. As investors seek exposure to AI stocks, biotech innovators, 5G connectivity leaders, and polymetallic miners, the momentum behind MIRA, PRSO, PNPNF, MYSE, WHWK, RDZN, and APRE reflects a broader shift toward data-driven, impact-oriented growth sectors shaping the next generation of opportunity.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com